Choi Jin Woo, Jo Anna, Kim Min, Park Ho Seon, Chung Sung Soo, Kang Shinae, Park Kyong Soo
Department of Internal Medicine, College of Medicine, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, South Korea.
Diabetologia. 2016 Mar;59(3):571-81. doi: 10.1007/s00125-015-3836-9. Epub 2015 Dec 22.
AIMS/HYPOTHESIS: Adipose tissue is a highly versatile system in which mitochondria in adipocytes undergo significant changes during active tissue remodelling. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a mitochondrial protein and a known mitochondrial quality regulator. In this study, we investigated the role of BNIP3 in adipocytes, specifically under conditions of peroxisome proliferator-activated receptor-γ (PPARγ)-induced adipose tissue remodelling.
The expression of BNIP3 was evaluated in 3T3-L1 adipocytes in vitro, C57BL/6 mice fed a high-fat diet and db/db mice in vivo. Mitochondrial bioenergetics was investigated in BNIP3-knockdown adipocytes after rosiglitazone treatment. A putative peroxisome proliferator hormone responsive element (PPRE) was characterised by promoter assay and electrophoretic mobility shift assay (EMSA).
The protein BNIP3 was more abundant in brown adipose tissue than white adipose tissue. Furthermore, BNIP3 expression was upregulated by 3T3-L1 pre-adipocyte differentiation, starvation and rosiglitazone treatment. Conversely, BNIP3 expression in adipocytes decreased under various conditions associated with insulin resistance. This downregulation of BNIP3 was restored by rosiglitazone treatment. Knockdown of BNIP3 in adipocytes inhibited rosiglitazone-induced mitochondrial biogenesis and function, partially mediated by the 5' AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor γ, co-activator 1 α (PGC1α) signalling pathway. Rosiglitazone treatment increased the transcription level of Bnip3 in the reporter assay and the presence of the PPRE site in the Bnip3 promoter was demonstrated by EMSA.
CONCLUSIONS/INTERPRETATION: The protein BNIP3 contributes to the improvement of mitochondrial bioenergetics that occurs on exposure to rosiglitazone. It may be a novel therapeutic target for restoring mitochondrial dysfunction under insulin-resistant conditions.
目的/假设:脂肪组织是一个高度多功能的系统,其中脂肪细胞中的线粒体在活跃的组织重塑过程中会发生显著变化。BCL2/腺病毒E1B 19 kDa蛋白相互作用蛋白3(BNIP3)是一种线粒体蛋白,也是一种已知的线粒体质量调节剂。在本研究中,我们研究了BNIP3在脂肪细胞中的作用,特别是在过氧化物酶体增殖物激活受体γ(PPARγ)诱导的脂肪组织重塑条件下的作用。
在体外3T3-L1脂肪细胞、高脂饮食喂养的C57BL/6小鼠和体内db/db小鼠中评估BNIP3的表达。在罗格列酮处理后的BNIP3敲低脂肪细胞中研究线粒体生物能量学。通过启动子分析和电泳迁移率变动分析(EMSA)对假定的过氧化物酶体增殖物激素反应元件(PPRE)进行表征。
蛋白质BNIP3在棕色脂肪组织中比白色脂肪组织中更丰富。此外,BNIP3的表达在3T3-L1前脂肪细胞分化、饥饿和罗格列酮处理后上调。相反,在与胰岛素抵抗相关的各种条件下,脂肪细胞中BNIP3的表达降低。罗格列酮处理可恢复BNIP3的这种下调。脂肪细胞中BNIP3的敲低抑制了罗格列酮诱导的线粒体生物发生和功能,部分由5'单磷酸腺苷激活蛋白激酶(AMPK)-过氧化物酶体增殖物激活受体γ共激活因子1α(PGC1α)信号通路介导。在报告基因分析中,罗格列酮处理增加了Bnip3的转录水平,并且通过EMSA证明了Bnip3启动子中存在PPRE位点。
结论/解读:蛋白质BNIP3有助于改善罗格列酮作用下的线粒体生物能量学。它可能是在胰岛素抵抗条件下恢复线粒体功能障碍的新治疗靶点。